Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

This study has been terminated.
(Live H1N1 vaccine expired and unable to get new supply)
Sponsor:
Collaborator:
Information provided by:
University of Rochester
ClinicalTrials.gov Identifier:
NCT01097941
First received: March 30, 2010
Last updated: October 27, 2010
Last verified: October 2010
  Purpose

A total of 51 children between the ages of 4 and 9 will be randomized to receive a two dose schedule of either licensed live attenuated A/California/07/09 influenza vaccine (LAIV) or licensed inactivated A/California/07/09 influenza vaccine (IIV) or IIV followed by LAIV separated by 28 days. Children with prior vaccination or natural infection with novel H1N1 influenza will be excluded. Randomization will be stratified by pre-existing HAI titers to the previous winter's seasonal H1N1 A/Brisbane/57/07 reference virus.


Condition Intervention Phase
2009 H1N1 Influenza
Biological: Live Attenuated H1N1 Influenza Vaccine
Biological: Influenza A (H1N1) 2009 Monovalent Vaccine
Biological: Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated A/California/07/09 H1N1 Influenza Vaccines in Children

Resource links provided by NLM:


Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C [ Time Frame: nasal swabs obtained at days 2 post vaccination ] [ Designated as safety issue: No ]
  • The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C [ Time Frame: nasal swab at 4 days post vaccination ] [ Designated as safety issue: No ]
  • The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C [ Time Frame: nasal swab obtained at 7 days post vaccination ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The AUC of nasopharyngeal shedding assessed by quantitative rtRT-PCR [ Time Frame: swabs will be obtained on day 2 post vaccination ] [ Designated as safety issue: No ]
  • The frequency and magnitude of serum hemagglutination-inhibition (HAI), ELISA, and neutralizing antibody response to vaccine [ Time Frame: at day 28 ] [ Designated as safety issue: No ]
  • The frequency and magnitude of hemagglutinin-specific mucosal IgA response assessed by ELISA on nasal secretions [ Time Frame: day 28 ] [ Designated as safety issue: No ]
  • The frequency and magnitude of antibody secreting cell and memory B cells developing after vaccination [ Time Frame: on day 7 ] [ Designated as safety issue: No ]
  • Development of specific local and systemic symptoms occuring after vaccine [ Time Frame: for 7 days post each vaccination ] [ Designated as safety issue: Yes ]
  • The AUC of nasopharyngeal shedding assessed by quantitative rtRT-PCR [ Time Frame: swab obtained at day 4 post vaccination ] [ Designated as safety issue: No ]
  • The AUC of nasopharyngeal shedding assessed by quantitative rtRT-PCR [ Time Frame: swab obtained at day 7 post vaccination ] [ Designated as safety issue: No ]
  • The frequency and magnitude of serum hemagglutination-inhibition (HAI), ELISA, and neutralizing antibody response to vaccine [ Time Frame: at day 56 ] [ Designated as safety issue: No ]
  • The frequency and magnitude of hemagglutinin-specific mucosal IgA response assessed by ELISA on nasal secretions [ Time Frame: at day 56 ] [ Designated as safety issue: No ]
  • The frequency and magnitude of antibody secreting cell and memory B cells developing after vaccination [ Time Frame: on day 35 ] [ Designated as safety issue: No ]

Estimated Enrollment: 51
Study Start Date: March 2010
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: LAIV/LAIV Biological: Live Attenuated H1N1 Influenza Vaccine
0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
Other Name: Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal
Active Comparator: IIV/IIV Biological: Influenza A (H1N1) 2009 Monovalent Vaccine
0.5 ml IM, 2 doses given 28 days apart
Other Name: Influenza vaccine
Active Comparator: IIV/LAIV Biological: Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
Other Name: Influenza Vaccine

Detailed Description:

The study will be conducted as a randomized, prospective, open-label evaluation of the clinical tolerability, vaccine virus shedding, and serum and mucosal antibody response to vaccination with either live monovalent novel H1N1 influenza vaccine (LAIV) or monovalent inactivated novel H1N1 influenza vaccine (IIV) in healthy children between the ages of 4 and 9 years. Children will be screened for antibody to A/Brisbane/57/07 (H1N1) and A/California/07/09 (H1N1) prior to randomization. Children with evidence of prior exposure to the 2009 pandemic H1N1 virus will be excluded. Those with antibodies to A/Brisbane/57/07 (H1N1) will be stratified by preexisting antibody. Vaccine will be administered on days 0 and 28.

Safety of vaccination will be assessed using symptoms collected by parents for 7 days after each dose of vaccine. Serum will be obtained prior to and on day 28 following each dose of vaccine and assessed for antibody by HAI, ELISA, B-cell ELISPOT and neutralization techniques. Nasal secretions will be obtained by nasal aspiration prior to and on day 28 after each dose and assessed for HA-specific IgA antibody by ELISA. Nasal swabs will be obtained on days 2, 4, and 7 after each dose of live vaccine and assessed for the presence and magnitude of vaccine virus shedding of the live attenuated vaccine by rtRT-PCR and TCID50 on MDCK cells.

  Eligibility

Ages Eligible for Study:   4 Years to 9 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Aged between 4 and 9 years, inclusive.
  • Pre-vaccination serum HAI titer to A/California/07/09 of 8 or less
  • No prior history of laboratory documented infection with novel H1N1 virus or immunization with novel H1N1 vaccine.
  • in good health, as determined by: vital signs (heart rate <140 bpm; blood pressure: systolic ≥ 90 mm Hg and ≤140 mm Hg; diastolic ≤ 90 mm Hg; oral temperature <100.0ºF); medical history; and targeted physical examination, when necessary, based on medical history. Stable medical condition is defined as: no recent increase in prescription medication, dose, or frequency of medication in the last 3 months and health outcomes of the specific disease are considered to be within acceptable limits in the last 6 months.
  • subject/parents are able to understand and comply with the planned study procedures, including being available for all study visits.
  • subject/parents have provided informed consent prior to any study procedures. (An assent will be obtained for all children 6 years and older)

Exclusion Criteria:

  • a previous history of vaccination against novel H1N1 virus or a laboratory documented history of previous novel H1N1 infection.
  • History of egg allergy or allergy to other components of vaccine.
  • History of wheezing.
  • immunosuppressed as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy.
  • has an active neoplastic disease.
  • has long-term (greater than 2 weeks) use of oral or parenteral steroids, or high-dose inhaled steroids (>800 mg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal and topical steroids are allowed).
  • received immunoglobulin or another blood product within the 3 months prior to enrollment in this study.
  • has received an inactivated vaccine within the 2 weeks or a live vaccine within the 4 weeks prior to enrollment in this study or plans to receive another vaccine within the next 28 days (or 56 days for vaccine naïve recipients).
  • has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses. These conditions include chronic conditions recognized as risk factors for influenza complications or as contraindications for live vaccination, including chronic cardiac (exclusive of hypertension) or pulmonary conditions (including asthma), diabetes mellitus, or renal impairment.
  • has an acute illness or an oral temperature greater than 99.9 degrees F (37.7 degrees C) within 3 days prior to enrollment or vaccination. Subjects who had an acute illness that was treated symptoms resolved are eligible to enroll as long as treatment is completed and symptoms resolve > 3 days prior to enrollment.
  • is currently participating or plans to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has received an experimental agent within 1 month prior to enrollment in this study, or expects to receive another experimental agent during participation in this study, or intends to donate blood during the study period.
  • has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
  • has a known human immunodeficiency virus, hepatitis B, or hepatitis C infection.
  • has a previous history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccination.
  • has any condition that the principal investigator (PI) believes may interfere with successful completion of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01097941

Locations
United States, New York
University of Rochester Medical Center, Vaccine Research Unit Room 3-5000
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Investigators
Principal Investigator: John J Treanor, MD University of Rochester
  More Information

Publications:

Responsible Party: John Treanor, MD, Department of Internal Medicine, Division of Infectious Diseases, University of Rochester Medical Center
ClinicalTrials.gov Identifier: NCT01097941     History of Changes
Other Study ID Numbers: URMC 09-007
Study First Received: March 30, 2010
Last Updated: October 27, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of Rochester:
Influenza
H1N1

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 01, 2014